Press Releases for CRGN

Press Releases
Celldex Therapeutics Announces Completed Acquisition of CuraGen Corporation
Celldex and CuraGen Stockholders Approve Acquisition of CuraGen Corporation
Celldex Therapeutics Announces Appointment of Larry Ellberger As Chairman of the Board
Celldex Reports Second Quarter and Six Month 2009 Financial Results
CuraGen Reports Second Quarter 2009 Financial Results
CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer
CuraGen Updates CR011-vcMMAE Data at ASCO
Celldex Therapeutics, Inc. Enhances Precision Targeted Immunotherapy Platform with the Acquisition of CuraGen Corporation
CuraGen to Present CR011-vcMMAE Data at ASCO
/C O R R E C T I O N -- CuraGen Corporation/
CuraGen Reports First Quarter 2009 Financial Results
CuraGen Announces Board of Director Changes
CuraGen's Board of Directors to Evaluate Strategic Initiatives
CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
CuraGen to Present at the Rodman & Renshaw Annual Global Investment Conference
CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
CuraGen Reports Third Quarter 2008 Financial Results
CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011-vcMMAE Phase II Trial Results on November 3, 2008
CuraGen Corporation Receives Notification from NASDAQ
CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
Wall Street Media Presents Exclusive Videos from the Needham Biotech Conference
CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
CuraGen to Present at The Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
CuraGen Corporation Regains NASDAQ Listing Compliance
CuraGen Sells 5 Million TopoTarget Shares for Approximately $12 Million - May 27 2008 12:43AM
CuraGen Repurchases $50.9 Million of 2011 Convertible Debt for $43.2 Million - Jun 1 2008 4:54PM
CuraGen Reports First Quarter 2008 Financial Results
CuraGen Sells Ownership of Belinostat to TopoTarget A/S
CuraGen Advances CR011-vcMMAE into Phase II